Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
A phase 2 open label trial to test a potential drug treatment for Rett syndrome, the leading
known genetic cause of severe neurological impairment in girls. The drug, Copaxone (generic
name - Glatiramer acetate) is medication FDA approved for the treatment of multiple
sclerosis. Copaxone's high safety profile has been documented in large cohorts of patients
for more than 12 years.